OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Study Summary

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Conditions

Cardiovascular Disease

Interventions / Drugs

Olpasiran Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment11000 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.158137+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.